The purpose of the study is to find out is AUTX-007 an investigational drug, can help treat or cure cancer.

In this study, we want to see if a new drug called LBS-007 can help treat or cure leukemia. We want to find out if it is safe and if it works well for people with this disease.

We are looking for a dose of the APVO436 in combination with venetoclax and azacitidine that can be administered safely to participants who have been diagnosed with AML.

In this study, we want to see how well a new drug called Quizartinib works for people with Leukemia who do not have a specific mutation called FLT3-ITD. We want to see if this new drug helps improve the condition.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Collect Biospecimens from subjects who are newly diagnosed with Acute Myeloid Leukemia (AML)

Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AK117 to patients with Leukemia

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL) that has transformed to aggressive lymphoma called Richter's Transformation (RT)? Then you may be able to participate in this study whose purpose is to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL). These are targeted immune-based therapies standardly used to treat lymphoma and/or other cancers that may also work well for RT